Spondylitis is a type of chronic inflammatory arthritis that primarily targets the spine and the joints where the spine meets the pelvis (the sacroiliac joints). Unlike ordinary back pain caused by muscle strain or disc problems, spondylitis is driven by an immune system that attacks the body’s own tissues, causing persistent inflammation that can eventually lead to new bone growth and, in severe cases, fusion of the vertebrae. It belongs to a broader family of conditions called spondyloarthritis, which can affect the spine, peripheral joints, and even organs like the eyes and gut.
How Spondylitis Differs From Regular Back Pain
The hallmark of spondylitis is inflammatory back pain, which behaves very differently from the mechanical back pain most people experience. Mechanical back pain typically flares with movement and feels better with rest. Inflammatory back pain does the opposite: it improves with exercise and activity, worsens with rest, and is often worst in the early morning hours. People with spondylitis frequently wake up stiff and sore, then gradually loosen up as they move through the day.
Experts use a specific checklist to identify inflammatory back pain. The key features include pain that starts before age 40, comes on gradually rather than after an injury, lasts at least three months, improves with exercise, does not improve with rest, and causes nighttime pain that gets better once you’re up and moving. Alternating buttock pain, where discomfort shifts from one side to the other, is another characteristic pattern. If four or more of these features are present, inflammatory back pain is likely.
Types of Spondyloarthritis
The broader spondyloarthritis family is divided into two main categories based on where inflammation concentrates. Axial spondyloarthritis affects the spine and sacroiliac joints. Peripheral spondyloarthritis primarily involves joints in the arms and legs, along with tendons and ligaments.
Axial spondyloarthritis is further split into two stages. When structural damage to the sacroiliac joints is visible on standard X-rays, the condition is classified as ankylosing spondylitis, the most well-known form. When inflammation is present but hasn’t yet caused X-ray-visible damage (though it may show up on MRI), it’s called non-radiographic axial spondyloarthritis. This distinction matters because many people spend years in the non-radiographic stage before changes appear on X-rays, and recognizing the condition early opens the door to treatment that can slow progression.
What Happens Inside the Spine
The primary target of spondylitis is the enthesis, the point where tendons, ligaments, and joint capsules anchor into bone. Inflammation at these attachment points, called enthesitis, causes the pain, stiffness, swelling, and loss of function that define the disease. Bone swelling (edema) and inflammation of the joint lining also contribute to symptoms.
What makes spondylitis unusual among inflammatory diseases is what comes next. After repeated cycles of inflammation, the body responds by laying down new cartilage and bone at the inflamed sites. Over time, these bony growths (called syndesmophytes when they form along the spine) can bridge the gaps between vertebrae. In advanced cases, the vertebrae fuse together, a process called ankylosis, which progressively limits spinal mobility. This new bone formation originates from the enthesis and the outer surface of the bone, growing outward in continuity with the existing skeleton.
Who Gets Spondylitis
Spondylitis predominantly affects young adults, with symptoms most commonly appearing in the thirties. Men are diagnosed three to four times more often than women, though the gender gap has been narrowing in recent years. In Korean population data tracked from 2010 to 2023, the proportion of female patients rose from about 18% to 24%, and the share of patients over age 50 grew from roughly 20% to 33%. These shifts likely reflect both genuine increases in disease recognition and improved diagnostic awareness, particularly in groups historically underdiagnosed.
Genetics play a significant role. A gene called HLA-B27 is found in about 85% of people with ankylosing spondylitis, compared to roughly 6 to 8% of the general population. Carrying the gene does not guarantee you’ll develop the disease (most HLA-B27-positive people never do), but it substantially increases the risk. Other genes and environmental factors are also involved, which explains why the remaining 10 to 15% of patients don’t carry HLA-B27 at all.
Beyond the Spine: Other Affected Organs
Spondylitis is not exclusively a joint disease. A large proportion of patients develop inflammation in other parts of the body, and these extra-articular manifestations can sometimes cause more day-to-day trouble than the back pain itself.
- Eye inflammation (anterior uveitis): The most common complication, affecting 25 to 30% of patients. It causes sudden pain, redness, and blurred vision in one eye and typically flares and resolves over several weeks, though repeated episodes can occur.
- Skin involvement (psoriasis): Occurs in 10 to 25% of people with spondyloarthritis, causing scaly, inflamed patches on the skin.
- Gut inflammation (inflammatory bowel disease): Between 5 and 10% of spondylitis patients develop Crohn’s disease or ulcerative colitis. The link runs both ways: about 10% of people with IBD eventually develop spondyloarthritis.
- Cardiovascular effects: Chronic inflammation raises the risk of heart and blood vessel problems over time.
These overlapping conditions influence treatment choices. A patient with recurring uveitis or active IBD, for example, will be steered toward different medications than someone with prominent skin disease.
How Spondylitis Is Diagnosed
Diagnosis typically combines clinical evaluation with imaging. The modified New York criteria, long considered the standard for ankylosing spondylitis, require evidence of sacroiliac joint damage on X-ray along with clinical features like inflammatory back pain and limited spinal motion. In one study of patients with inflammatory back pain, 82% had X-ray-visible sacroiliac changes, and applying the modified criteria identified all of them.
The limitation of X-ray-based criteria is that structural damage can take years to develop. MRI can detect inflammation much earlier, which is why the newer classification system for axial spondyloarthritis includes MRI findings alongside clinical signs, blood markers like elevated C-reactive protein, and HLA-B27 status. This allows earlier identification and treatment, before permanent bone changes set in.
Doctors also use standardized scoring tools to track disease activity over time. The preferred tool, called ASDAS, combines patient-reported symptoms with a blood marker of inflammation (C-reactive protein) to produce a single score. An older tool called BASDAI relies solely on patient-reported symptoms and is used as a backup when blood testing isn’t available. These scores guide decisions about starting, adjusting, or continuing treatment.
Treatment Options
The first line of treatment for spondylitis is regular exercise and physical therapy, which directly targets the stiffness and loss of mobility that define the condition. Structured exercise programs focusing on flexibility, posture, and core strength are a core part of long-term management, not just an add-on.
Anti-inflammatory medications (NSAIDs like ibuprofen or naproxen) are the standard first medication, and many people find they provide significant relief. For patients whose disease remains active despite consistent use of these medications, biologic therapies are the next step.
The two most commonly used classes of biologics target specific immune signaling molecules. One class blocks a protein called TNF that drives inflammation. The other blocks a protein called IL-17 involved in a different inflammatory pathway. A third option, JAK inhibitors (taken as pills rather than injections), is also available but typically reserved for cases where the first two classes aren’t suitable, since there’s less long-term clinical experience with them.
The choice between these biologics is not one-size-fits-all. Current guidelines from the leading international spondylitis organizations recommend TNF blockers for patients who also have recurring eye inflammation or active inflammatory bowel disease, since these drugs address those conditions simultaneously. IL-17 blockers are generally preferred for patients with significant psoriasis. This tailored approach means that the combination of symptoms you have, not just your back pain, shapes your treatment plan.
Long-Term Outlook
Spondylitis is a lifelong condition, but outcomes have improved dramatically with modern treatments. The goal of therapy is to reduce inflammation enough to prevent new bone formation and preserve spinal flexibility. Many people with well-managed disease maintain full, active lives with minimal limitations.
The biggest risk factor for poor outcomes is delayed diagnosis. On average, people with spondylitis wait years between their first symptoms and a correct diagnosis, partly because back pain is so common and partly because early disease doesn’t always show up on X-rays. Younger people with persistent back pain lasting more than three months that improves with movement and worsens with rest, especially those with a family history of spondylitis or related conditions, benefit most from early evaluation.